Dicerna Pharmaceuticals, Inc. (DRNA) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) from a buy rating to a hold rating in a research note released on Tuesday, November 7th.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 price objective (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. ValuEngine raised shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, November 2nd. Finally, Chardan Capital reaffirmed a hold rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $6.81.

Shares of Dicerna Pharmaceuticals (DRNA) traded up $0.14 on Tuesday, reaching $9.58. 77,746 shares of the company traded hands, compared to its average volume of 277,639. Dicerna Pharmaceuticals has a 12 month low of $2.42 and a 12 month high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company had revenue of $0.47 million for the quarter. During the same period in the prior year, the company earned ($0.68) earnings per share. The company’s revenue for the quarter was up 192.6% on a year-over-year basis. analysts forecast that Dicerna Pharmaceuticals will post -3.04 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. UBS Group AG lifted its position in shares of Dicerna Pharmaceuticals by 0.6% during the 1st quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares in the last quarter. Northern Trust Corp increased its stake in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Dicerna Pharmaceuticals by 2.4% in the 1st quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after acquiring an additional 9,818 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Dicerna Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its holdings in Dicerna Pharmaceuticals by 4.0% during the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after acquiring an additional 19,394 shares during the period. Hedge funds and other institutional investors own 51.84% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/dicerna-pharmaceuticals-inc-drna-downgraded-by-zacks-investment-research-to-hold/1763710.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.